OR WAIT null SECS
The companies entered a license agreement for the Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies (mAbs), to support MacroGenics’ discovery programs for mAb-based therapeutics.
Trianni, a biotech company specializing in antibody discovery technology, and MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody (mAb)-based therapeutics to treat cancer, announced on Dec. 6, 2018 that they have entered into a license agreement for the Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully-human mAbs, to support MacroGenics’ discovery programs for mAb-based cancer therapeutics.
Financial details of the deal were not disclosed.
Trianni states that, through its Mouse platform, transgenic mice are generated via replacement of the endogenous V, D, and J segments of their genome by antibody genes that are optimized to function in the mouse while expressing a complete repertoire of human variable domains. Highly engineered H, K, and L loci are chemically synthesized and integrated into native chromosomal locations. The resulting transgenic mice possess the same antibody repertoire as humans yet produce wild-type mouse antibody responses to target antigens.
“With the Trianni Mouse in our discovery toolbox, MacroGenics now has the ability to incorporate fully human antibody sequences into molecules that are based on our Fc optimization and multi-specific DART and Trident platforms, further accelerating our discovery and candidate development processes,” said Ezio Bonvini, MD, chief scientific officer of MacroGenics, in a company press release.